Lepu Biopharma (2157.HK) announces 2025 interim results
Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025.
August 21, 2025
by ACN Newswire
NUZ-001 OLE Study Demonstrates Long-Term Safety and Efficacy Signals
Neurizon® Therapeutics Limited is pleased to report positive topline results from the Open-Label Extension study of its lead candidate NUZ-001, for the treatment of amyotrophic lateral sclerosis , the major form of motor neurone disease.
August 20, 2025
by Biotech Newswire